There is encouraging news for those coping with the challenges of an enlarged prostate or benign prostatic hyperplasia (BPH). Recently, the U.S. Food and Drug Administration (FDA) has cleared new indications for the UroLift® System, a minimally invasive procedure that inserts permanent implants in the urethra, relieving prostate obstructions. Patients as young as 45 with BPH are now eligible to receive treatment.
“Urolift is a new, minimally invasive surgical technique for the treatment of BPH,” shared Thomas Clements, a urologist with Urology of Central Pennsylvania. “It is a simple outpatient or in-office procedure that can significantly improve patients’ quality of life.”
Typically, medication is the first line of therapy for enlarged prostate symptoms. The alternative is surgery, but both have undesirable side effects. The UroLift® System is able to relieve quickly patients’ symptoms, while preserving their quality of life.
“[UroLift®] can often lead to patients not needing to take medications anymore,” said Dr. Clements. “To say the least, the procedure yields huge clinical benefits with minimal risk. Also, in many cases, a catheter isn’t required.”
UCPA is proud to offer this effective treatment option to our patients and we have been encouraged by its success. For more information on BPH, click here. For more information on the UroLift® System, click here. To speak with someone about UroLift, please call (717) 724-0720 or (717) 763-1174.